Previous 10 | Next 10 |
Immune Therapeutics Announces Settlement with Major Creditors as part of licensing agreement Immune Therapeutics Announces Filing of 10K Extension Under SEC Allowance for COVID19 Disruption Forte Aims to Develop and Commercialize Lodonal and IRT=101 for the Treatment of Cancer and ...
Orlando, Florida--(Newsfile Corp. - March 20, 2020) - Immune Therapeutics, Inc. (OTC Pink: IMUN) ("Immune" "IMUN" or the "Company"), Immune Therapeutics, Inc., a late-stage clinical biopharmaceutical company focused on the development and commercialization of highly innovative therapies for us...
Orlando, Florida--(Newsfile Corp. - March 9, 2020) - Immune Therapeutics, Inc. (OTC Pink: IMUN) ("Immune" "IMUN" or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of therapies for the treatment of autoimmune diseases, inflammatory diseases and cancer...
Fort Collins, Colorado--(Newsfile Corp. - February 18, 2020) - Immune Therapeutics, Inc. (OTC Pink: IMUN) ("Immune" "IMUN" or the "Company") is a late-stage biopharmaceutical company focused on the development of T-cell activation immunotherapy to treat life-threatening or chronic diseases tha...
Orlando, Florida--(Newsfile Corp. - February 11, 2020) - Immune Therapeutics, Inc. (OTC Pink: IMUN) ("Immune" "IMUN" or the "Company"), a clinical late stage biopharmaceutical company focused on the development of therapies for the treatment of autoimmune diseases, inflammatory diseases today ...
ORLANDO, Fla., Dec. 16, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Immune Therapeutics, Inc. (OTCQB: IMUN) ("Immune", “IMUN” or the "Company") and Aletheia Therapeutics Corp. (“Aletheia”), a privately held development-stage oncology therapeutics company, today a...
ORLANDO, Fla., Oct. 28, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE – Immune Therapeutics, Inc. (OTC:IMUN) (IMUN) (“Immune” “IMUN” or the “Company”), a clinical late-stage oncology biopharmaceutical company focused on the development therapies f...
ORLANDO, Fla., Oct. 22, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Immune Therapeutics, Inc. (OTCQB: IMUN) ("Immune" “IMUN” or the "Company"), a clinical late-stage biopharmaceutical company focused on the development of therapies for the treatment of autoimmune diseases, inf...
ORLANDO, Fla., Sept. 26, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE – Immune Therapeutics, Inc. (OTC: IMUN) ("Immune," “IMUN” or the "Company"), a clinical late stage biopharmaceutical company focused on the development of immunomodulating therapies for the treatment of a...
ORLANDO, Fla., Sept. 23, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE – Immune Therapeutics, Inc. (OTC:IMUN) (IMUN) (“Immune” “IMUN” or the “Company”), a clinical late-stage T-Cell Activation biopharmaceutical company focused on the development i...
News, Short Squeeze, Breakout and More Instantly...
Orlando, FL, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Immune Therapeutics, Inc. d/b/a Biostax Corp (OTC Pink: IMUN) (“Biostax”), a hub and spoke biotech development engine, sadly announces the passing of H. Louis Salomonksy, a dedicated member of its Board of Directors. Mr. Salomonksy pas...
Orlando, FL, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Immune Therapeutics, Inc. d/b/a Biostax Corp . (OTC Pink: IMUN) (“Biostax”), a hub-and-spoke biotech development engine, announces the signing of a research collaboration agreement with Immgenuity, Inc . The joint resear...
Orlando, FL, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Immune Therapeutics, Inc. d/b/a Biostax Corp. (OTC Pink: IMUN) ("Biostax"), a hub-and-spoke biotech development engine, announces that they have accepted the transfer of three Investigational New Drug Applications (IND) for the drug candidate, JKB-12...